Table 1.
Demographic factors and disease severity in patients in the Rapid Evaluation Program and the overall expanded access program† patients.
| Rapid evaluation project sample† | EAP cohort† | |
|---|---|---|
| Patient characteristics | ||
| Total patients enrolled | 9,752 | 73,258 |
| Enrolled patients that received a transfusion | 8,311 | 64,987 (100.0%)* |
| Patients excluded due to insufficient follow-upa | 381 | – |
| Received >1 transfusionb | 534 | 3,880 (6.0%) |
| Patients included in the analysis | 7,164 (100%)* | – |
| Patient outcomes | ||
| Discharge reportedc | 4,435 (60.0%) | 44,926 (69.1%) |
| Death reported | 1,659 (22.4%) | 18,650 (28.7%) |
| Geographic region | ||
| Midwest | 1,473 (20.6%) | 9,079 (14.0%) |
| Northeast | 913 (12.7%) | 11,410 (17.6%) |
| Puerto Rico | 13 (0.2%) | 67 (0.1%) |
| Southeast | 2,252 (31.4%) | 18.979 (29.2%) |
| Southwest | 1,077 (15.0%) | 16,161 (24.9%) |
| West | 1,436 (20.0%) | 9,289 (14.3%) |
| Categorical age (years) | ||
| 18–34 | 406 (5.7%) | 3,661 (5.6%) |
| 35–54 | 1,983 (27.7%) | 17,236 (26.5%) |
| 55–79 | 3,946 (55.1%) | 36,682 (56.4%) |
| 80 or older | 829 (11.6%) | 7,408 (11.4%) |
| Gender | ||
| Female | 2,872 (40.2%) | 26,281 (40.5%) |
| Male | 4,267 (59.7%) | 38,472 (59.4%) |
| Undisclosed | 7 (0.1%) | 64 (0.1%) |
| Race | ||
| Asian | 251 (3.5%) | 2,211 (3.4%) |
| Black or African American | 1,423 (19.9%) | 11,864 (18.3%) |
| Other or unknown | 1,840 (25.7%) | 17,170 (26.4%) |
| White | 3,650 (50.9%) | 33,742 (51.9%) |
| Ethnicity | ||
| Hispanic/latino | 2,494 (34.8%) | 25,640 (39.5%) |
| Not hispanic/latino | 4,670 (65.2%) | 39,347 (60.5%) |
| Initial clinical status | ||
| Mild or moderate | 2,295 (34.0%) | 4,196 (37.0%) |
| Severe | 2,921 (43.3%) | 4,741 (41.8%) |
| Critical or end stage | 1,516 (22.5%) | 2,370 (20.9%) |
| Medications received during hospital stay | ||
| Angiotensin receptor blockers (ARBs) | 455 (7.2%) | 2,751 (6.7%) |
| ACE Inhibitors | 584 (9.2%) | 3,529 (8.6%) |
| Azithromycin | 3,029 (47.7%) | 20,043 (49.0%) |
| Remdesivir | 2,823 (44.5%) | 15,608 (38.2%) |
| Steroids | 4,074 (64.2%) | 26,843 (65.7%) |
| Hydroxychloroquine and/or chloroquine | 646 (10.2%) | 7,323 (17.9%) |
†
All enrollment information as of August 3, 2020.
*
Following subsections of the same column are based on this value.
a
Insufficient follow-up include, no daily reporting for a patient, no dates of submitted reports.
b
Defined as >4 h between transfusions. Multiple units given within 4 h were considered a single transfusion.
c
Number of patients reported discharged or expired within 21 days of convalescent plasma treatment.